Abstract
Recent research advances have defined a key role of the bone marrow (BM) in multiple myeloma (MM) pathogenesis thereby leading to new treatment paradigms, which aim to target both the tumor cell as well as its BM microenvironment. The incorporation of thalidomide, bortezomib, and lenalidomide into conventional cytotoxic and transplantation regimens in relapsed and refractory, but also in newly diagnosed MM has changed treatment options during the last decade. However, MM remains still incurable. Ongoing translational research aims to identify additional therapeutic targets and to design derived agents, predominantly small molecule inhibitors, with higher potency and less toxicity to further improve MM patient outcome and to overcome drug resistance.
Keywords: Bone marrow microenvironment, bortezomib, carfilzomib, combination therapy, HDAC inhibitors, lenalidomide, multiple myeloma, pomalidomide, small molecule inhibitors, thalidomide, Array- comparative genomic hybridization, Extracellular signal related kinase, Farnesyltransferase inhibitors, Leukemia inhibitory factor, Microvessel density.
Current Cancer Drug Targets
Title:Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma
Volume: 12 Issue: 7
Author(s): Klaus Podar
Affiliation:
Keywords: Bone marrow microenvironment, bortezomib, carfilzomib, combination therapy, HDAC inhibitors, lenalidomide, multiple myeloma, pomalidomide, small molecule inhibitors, thalidomide, Array- comparative genomic hybridization, Extracellular signal related kinase, Farnesyltransferase inhibitors, Leukemia inhibitory factor, Microvessel density.
Abstract: Recent research advances have defined a key role of the bone marrow (BM) in multiple myeloma (MM) pathogenesis thereby leading to new treatment paradigms, which aim to target both the tumor cell as well as its BM microenvironment. The incorporation of thalidomide, bortezomib, and lenalidomide into conventional cytotoxic and transplantation regimens in relapsed and refractory, but also in newly diagnosed MM has changed treatment options during the last decade. However, MM remains still incurable. Ongoing translational research aims to identify additional therapeutic targets and to design derived agents, predominantly small molecule inhibitors, with higher potency and less toxicity to further improve MM patient outcome and to overcome drug resistance.
Export Options
About this article
Cite this article as:
Podar Klaus, Novel Targets and Derived Small Molecule Inhibitors in Multiple Myeloma, Current Cancer Drug Targets 2012; 12 (7) . https://dx.doi.org/10.2174/156800912802429319
DOI https://dx.doi.org/10.2174/156800912802429319 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Erythropoietin in Heart Failure and Other Cardiovascular Diseases: Hematopoietic and Pleiotropic Effects
Current Drug Targets - Cardiovascular & Hematological Disorders The High Mobility Group A1 (HMGA1) Transcriptome in Cancer and Development
Current Molecular Medicine Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy The Recent Progresses on The Improved Therapy of Melanoma by Novel Drug Delivery Systems
Current Drug Targets Transplantation and Other Uses of Human Umbilical Cord Blood and Stem Cells
Current Pharmaceutical Design VEGF in the Muscular Layer of Placental Blood Vessels: Immuno- Expression in Preeclampsia and Intrauterine Growth Restrictrion and its Association with the Antioxidant Status
Cardiovascular & Hematological Agents in Medicinal Chemistry Desensitization Protocol for Rituximab-Induced Serum Sickness
Current Drug Safety P-glycoprotein Inhibition as a Therapeutic Approach for Overcoming Multidrug Resistance in Cancer: Current Status and Future Perspectives
Current Cancer Drug Targets Anti-cancer and Other Bioactivities of Korean Angelica gigas Nakai (AGN) and Its Major Pyranocoumarin Compounds
Anti-Cancer Agents in Medicinal Chemistry Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Current Cancer Drug Targets Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases
Current Neuropharmacology Hematopoietic Cell Formation in Leech Wound Healing
Current Pharmaceutical Design Antitumor Effect of Pomolic Acid in Acute Myeloid Leukemia Cells Involves Cell Death, Decreased Cell Growth and Topoisomerases Inhibition
Anti-Cancer Agents in Medicinal Chemistry Genetics, Gene Expression, and Targeted Therapies in Chronic Lymphocytic Leukemia
Current Drug Targets HLAs in Autoimmune Diseases: Dependable Diagnostic Biomarkers?
Current Rheumatology Reviews Infrequent Infections in COPD
Current Respiratory Medicine Reviews Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews PET Radiopharmaceuticals for Personalized Medicine
Current Drug Targets Rituximab Therapy and Autoimmune Disease
Current Immunology Reviews (Discontinued)